Finance

Lists
INDV:NASDAQ
Indivior Pharmaceuticals Inc
36,28 USD
0,00%
(0,00) 1D
36,41 USD
+0,36% (+0,13)
After hours
Closed: 2-ноя., 16:00:01 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INDV...
Mkt. cap
5,86 млд
Avg. vol.
2,44 млн
Volume
0,00
P/E ratio
13,06
52-wk high
42,81 USD
52-wk low
27,68 USD
EPS
2,78 USD
Beta
1,10
Shares outstanding
118,04 млн
No. of employees
833
Mkt. cap
5,86 млд
Avg. vol.
2,44 млн
Volume
0,00
P/E ratio
13,06
52-wk high
42,81 USD
52-wk low
27,68 USD
EPS
2,78 USD
Beta
1,10
Shares outstanding
118,04 млн
No. of employees
833
News stories
From web sources and news partners
Profile
Indivior is an American pharmaceuticals company. Established as a division of Reckitt Benckiser in 1994 and demerged from that company in December 2014, it is focussed on substitution products for opioid addiction. It is listed on the London Stock Exchange and on the NASDAQ Global Select Market. Wikipedia
About Indivior Pharmaceuticals Inc
CEOMark Crossley
Employees833
Founded2014-ж., 26-сен.
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Analyst ratings
Based on 2 analysts giving stock ratings to INDV in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for INDV in the last 3 months.
Highest
Current 36,28 USD
45,00 USD (+24,04%)
Average
45,00 USD (+24,04%)
Lowest
45,00 USD (+24,04%)
Analyst
Recommendation
Action
Price target
Projected
Date
Glen Santangelo
Barclays
Buy
Maintained
45,00 USD
+24%
10/28/2026
Chase Knickerbocker
Craig-Hallum
Buy
Maintained
-
-
09/17/2026
Brandon Folkes
H.C. Wainwright
Buy
Reiterated
48,00 USD
+32,3%
08/04/2026
David Amsellem
Piper Sandler
Buy
Reiterated
59,00 USD
+62,6%
05/22/2026
Carl Byrnes
Northland Securities
Buy
Maintained
50,00 USD
+37,8%
02/27/2026
Last report
2026-ж., 29-окт.
Fiscal period
Q3 2026
1,32 USD / 1,13 USD
+17,23%beat
Revenue / Est. (USD)
356,00 млн / 329,35 млн
+8,09%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
358,00 млн
317,00 млн
343,00 млн
356,00 млн
Cost of goods sold
56,00 млн
40,00 млн
48,00 млн
51,00 млн
Cost of revenue
56,00 млн
40,00 млн
48,00 млн
51,00 млн
Research and development expenses
17,00 млн
9,00 млн
12,00 млн
5,00 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
155,00 млн
122,00 млн
122,00 млн
105,00 млн
Operating expense
169,00 млн
131,00 млн
134,00 млн
110,00 млн
Total operating expenses
225,00 млн
171,00 млн
182,00 млн
161,00 млн
Operating income
133,00 млн
146,00 млн
161,00 млн
195,00 млн
Other non operating income
-
-
-
-1,00 млн
EBT including unusual items
81,00 млн
115,00 млн
160,00 млн
182,00 млн
EBT excluding unusual items
133,00 млн
142,00 млн
162,00 млн
196,00 млн
Income tax expense
-21,00 млн
26,00 млн
38,00 млн
45,00 млн
Effective tax rate
-25,93%
22,61%
23,75%
24,73%
Other operating expenses
-3,00 млн
-
-
-
Net income
102,00 млн
89,00 млн
122,00 млн
137,00 млн
Net profit margin
28,49%
28,08%
35,57%
38,48%
Earnings per share
0,82
0,96
1,15
1,32
Interest and investment income
6,00 млн
3,00 млн
3,00 млн
4,00 млн
Interest expense
-6,00 млн
-7,00 млн
-2,00 млн
-2,00 млн
Net interest expenses
-
-4,00 млн
1,00 млн
2,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
135,00 млн
148,00 млн
163,00 млн
196,00 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google колдонмолору